Akebia Therapeutics, Inc. (AKBA)


NasdaqGM - NasdaqGM Real Time Price. Currency in USD
8.11+0.02 (+0.25%)
At close: 4:00 PM EDT
People also watch:
AKAOAERIVSARAGTCCNCE
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open8.16
Prev Close8.09
Bid7.12 x 100
Ask0.00 x
Day's Range7.90 - 8.20
52wk Range6.40 - 14.20
1y Target EstN/A
Market Cap308.27M
P/E Ratio (ttm)-2.69
BetaN/A
Volume133,383
Avg Vol (3m)222,773
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Business Wire5 days ago

    Akebia Announces Publication Highlighting Need for New Solutions in Treating Dialysis Patients

    Akebia Therapeutics, Inc. , a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor , today announced the publication of a retrospective analysis indicating persistently greater mortality in dialysis-dependent chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponse .

  • Calculating The Impact Of Akebia Therapeutics Inc (AKBA)’s Pivotals
    Insider Monkey15 days ago

    Calculating The Impact Of Akebia Therapeutics Inc (AKBA)’s Pivotals

    Akebia Therapeutics Inc (NASDAQ:AKBA) just gave word of the initiation of its pivotal trial in a second indication for its lead renal anemia candidate, Vadadustat. The company already has one trial running, which kicked off late 2015, in non-dialysis dependent patients with anemia related to chronic kidney disease. This second indication is for the same […]

  • Why Akebia Therapeutics (AKBA) Could Be Positioned for a Slump
    Zacks15 days ago

    Why Akebia Therapeutics (AKBA) Could Be Positioned for a Slump

    Akebia Therapeutics (AKBA) has witnessed a significant price decline in the past four weeks, and it has lately seen negative earnings estimate revisions as well.